Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With IQVIA RDS Inc., Calyx, Laboratory Corporation of America, Medidata Solutions and 4 more.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
53actual
Sites
41
Countries
Argentina, Australia, Belgium +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-07-01 | actual | When the study began enrolling |
| Primary completion | 2026-08-14 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-08-19 | estimated | The whole study's end, after follow-up |
| First posted | 2022-03-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Erosive Esophagitis
Interventions
- Drug: Nexium 20mg
- Drug: Nexium 10mg
Primary outcome
what the primary-completion date above is the date OFPresence / absence of Erosive Esophagitis
measured Week 24 (end of 16-week maintenance phase)
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed